Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Hypoglycemia

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antigen-specific tolerance therapies in type 1 diabetes: Disease-specific promises meet stage-specific challenges.

Autoimmunity reviews·2026

Same author

Development of a comprehensive real-world evidence dataset to inform diabetes policy: the diabetes data cell project.

BMC public health·2026

Same author

Exploring the psychosocial implications of general population screening for paediatric type 1 diabetes in Europe: Protocol for a mixed-methods study.

Diabetic medicine : a journal of the British Diabetic Association·2026

Same author

Insights for personalized choice of a hybrid closed-loop system: an expert opinion.

Diabetes research and clinical practice·2026

Same author

A global initiative to deliver precision health in diabetes.

Nature medicine·2024

Same author

Cost of care pathways before and after appropriate and inappropriate transfers to the emergency department among nursing home residents: results from the FINE study.

BMC geriatrics·2024

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled

J Hermanides¹, K Nørgaard, D Bruttomesso

¹Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands. j.hermanides@amc.uva.nl

Diabetic Medicine : a Journal of the British Diabetic Association

|February 8, 2011

Summary

This summary is machine-generated.

Sensor-augmented insulin pump therapy significantly improved glycemic control in Type 1 diabetes patients. This advanced treatment lowered HbA1c levels effectively without increasing hypoglycemia risk compared to multiple daily injections.

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Related Experiment Videos

Last Updated: Jun 4, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Area of Science:

Endocrinology
Metabolic Diseases
Diabetes Technology

Background:

Type 1 diabetes management often involves multiple daily injections (MDI).
Suboptimal glycemic control (HbA1c ≥ 8.2%) necessitates exploring advanced therapeutic options.
Continuous glucose monitoring integrated with insulin pumps offers potential benefits.

Purpose of the Study:

To compare the efficacy of sensor-augmented insulin pump (SAP) therapy against MDI in Type 1 diabetes patients with suboptimal glycemic control.
To assess changes in HbA1c, sensor-derived metrics, and patient-reported outcomes.

Main Methods:

An investigator-initiated, multi-center trial (Eurythmics Trial) randomized 83 Type 1 diabetes patients (HbA1c ≥ 8.2%) to either SAP therapy (n=44) or MDI (n=39) for 26 weeks.
Primary endpoint was the change in HbA1c from baseline to 26 weeks.
Secondary endpoints included sensor-derived glycemic control and patient-reported outcomes.

Main Results:

SAP therapy significantly reduced HbA1c by -1.21% (P < 0.001) compared to MDI over 26 weeks.
The SAP group achieved target HbA1c levels (7.23%) without an increase in hypoglycemia.
Patient-reported outcomes, including diabetes management satisfaction, improved in the SAP group.

Conclusions:

Sensor-augmented pump therapy is an effective strategy for improving glycemic control in Type 1 diabetes patients previously managed with MDI.
SAP therapy offers a viable alternative for patients with suboptimally controlled Type 1 diabetes, enhancing both clinical and patient-reported outcomes.